SITC Clinical Immuno-Oncology Network (SCION) Workshop

Jan. 17–21, 2023 | Austin, TX
The Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) Workshop is an intimate immunotherapy clinical trial development program, led by experts in the field who are equipped to help their assigned students navigate through the unique considerations that accompany immunotherapy treatments.

Designed to address the unique considerations for designing clinical trial protocols focused on cancer immunotherapy, the SCION Workshop connects participants with experienced faculty in the field and dedicated patient advocates to advise on clinical trial protocol development.

ORGANIZERS

• Elizabeth Garrett-Mayer, PhD – American Society of Clinical Oncology
• Isabella C. Glitza Oliva, MD, PhD – The University of Texas MD Anderson Cancer Center
• Michael Lotze, MD, FACS – Nurix Therapeutics
• Chris Takimoto, MD, PhD – IGM Biosciences

PROGRAM FACULTY

• Tammy Benter, BS, MBA – Breast Cancer Resource Center
  
• Cody Chiuzan, PhD – Institute of Health System Science, Northwell Health
  
• Cynthia Chmielewski, BA - Health Tree Foundation for Myeloma
• Laura Q.M. Chow, MD – The University of Texas at Austin
  
• Deborah Collyar, Bsci – Patient Advocates in Research
  
• Leslie Cope, PhD – Johns Hopkins University
• Tricia Cottrell, MD, PhD – Queen's University
• Shelley Dodt, LCSW - Pennies in Action
• Elizabeth Garrett-Mayer, PhD – American Society of Clinical Oncology
• Isabella C. Glitza Oliva, MD, PhD – The University of Texas MD Anderson Cancer Center
• Paola Grandi, PhD – CG Oncology
  
• Susan Halabi, PhD – Duke University
  
• Elizabeth G. Hill, PhD – The Medical University of South Carolina
  
• Brian Hobbs, PhD - Dell Medical School at the University of Texas
• Gary Kohanbash, PhD – University of Pittsburgh
  
• Lewis Lanier, PhD – University of California, San Francisco
  
• Bryan Lewis, JD - KidneyCAN
• Michael Lotze, MD, FACS – Nurix Therapeutics
• Yana G. Najjar, MD – University of Pittsburgh
  
• Marie Recine, MS, MT (ASCP) - Freelance Patient Advocate/Medical Writer
• Ryan J. Sullivan, MD – Harvard Medical School and Massachusetts General Hospital
  
• Chris Takimoto, MD, PhD – IGM Biosciences
• Todd A. Triplett, PhD – Dell Medical School at the University of Texas at Austin
  
• Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Cancer Center

TARGET AUDIENCE

Eligible applicants are those working in the field of cancer immunotherapy who want to develop their own immunotherapy clinical trial protocol synopsis (resulting in an approved protocol and consent). This includes, but is not limited to, clinical fellows and junior faculty/attendings with medical, surgical, radiation, urologic, gynecologic, or pediatric oncology training and advanced degree scientists (e.g., Masters, PhD, PharmD, DNP) with research experience and interest in clinical and translational immuno-oncology. Applicants can be from academic, non-profit, or for-profit organizations, including the pharmaceutical industry/biotechnology.  Those with other related professional degrees are also encouraged to apply.

LEARNING OBJECTIVES

At the conclusion of the SCION Workshop, participants should be able to:

• Recognize best practices and overcome the unique challenges in clinical trial design specific to cancer immunotherapy
• Describe cancer immunotherapy clinical trial endpoints, biomarker development and validation and combination strategies
• Develop their own clinical trial design with appropriate clinical and biomarker endpoints, and draft a protocol and informed consent
• Estimate cost, process steps, quality issues, and regulatory path for development and approval of advanced therapy medicinal products (ATMPs)
• Understand the special issues associated with ATMPs, medicines based on genes, tissues or cells in Oncology

In addition to deepening their understanding of integral facets of the field of cancer immunotherapy, attendees will expand their professional network, developing new relationships with faculty and other thought leaders in this intimate setting.

Martin “Mac” Cheever Excellence in Clinical Trial Design - Travel Award

Established in 2022 in loving memory of Dr. Martin “Mac” Cheever, this fund recognizes his many contributions to the field of cancer immunotherapy by providing travel awards to deserving early career investigators pursuing excellence in clinical trial design.

Each year, SITC will identify the best and brightest in the field to continue Dr. Cheever’s passion for improving immunotherapy protocols through the Martin “Mac” Cheever Excellence in Clinical Trial Design - Travel Award.  This select group of deserving early career investigators will look to advance cancer immunotherapy through simple and elegant clinical trial design.  

The awardee will be selected from the participants in the SITC’s Clinical Immuno-Oncology Network (SCION) Workshop as having the most simple and elegant protocol at the close of the intensive and selective workshop.  

The awardee will receive flight, hotel, and meal reimbursement to fully support his/her travel to the SITC Annual Meeting in the same year that he/she is selected as the recipient of the award.

Registration

Registration is contingent upon acceptance to the SCION program.You will be contacted directly with specific instruction on how to register.

Registration Rates

Student Member	$1,000
Student Non-Member	$1,100
General Member	$1,500
General Non-Member	$1,800
Industry Member	$2,000
Industry Non-Member	$2,500

SCION participants will be expected to cover costs for all travel and lodging during the SCION workshop. The registration cost will include participation in some supplemental sessions of the Cancer Immunotherapy Winter School.